Ertumaxomab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ertumaxomab ?
Monoclonal antibody
Type Trifunctional antibody
Source Rat/mouse hybrid
Target HER2/neu, CD3
Clinical data
Trade names Rexomun
Legal status ?
Identifiers
CAS number 509077-99-0 N
ATC code None
Chemical data
Formula ?
 N (what is this?)  (verify)

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[1]

It is a so-called trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[2]

References[edit]